Our aim was to examine whether AI assistance could ameliorate the interobserver variability associated with the evaluation of HER2, ER, and PR status in breast cancer, and subsequent impact on the determination of molecular subtypes of breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.